|
TWI238064B
(en)
*
|
1995-06-20 |
2005-08-21 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
|
US5859037A
(en)
*
|
1997-02-19 |
1999-01-12 |
Warner-Lambert Company |
Sulfonylurea-glitazone combinations for diabetes
|
|
CN1168451C
(zh)
*
|
1997-06-18 |
2004-09-29 |
史密丝克莱恩比彻姆有限公司 |
噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途
|
|
US20020004515A1
(en)
*
|
1997-06-18 |
2002-01-10 |
Smith Stephen Alistair |
Treatment of diabetes with thiazolidinedione and metformin
|
|
US20010049380A1
(en)
*
|
1997-06-18 |
2001-12-06 |
Smith Stephen Alistair |
Treatment of diabetes with thiazolidinedione and sulphonylurea
|
|
CN1114404C
(zh)
*
|
1997-06-18 |
2003-07-16 |
史密丝克莱恩比彻姆有限公司 |
用噻唑烷二酮和二甲双胍治疗糖尿病
|
|
GB9715306D0
(en)
*
|
1997-07-18 |
1997-09-24 |
Smithkline Beecham Plc |
Novel method of treatment
|
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
|
US7105552B2
(en)
|
1998-05-08 |
2006-09-12 |
Theracos, Inc. |
Heterocyclic analogs of diphenylethylene compounds
|
|
CN1312807A
(zh)
|
1998-06-19 |
2001-09-12 |
希龙公司 |
糖元合成酶激酶3的抑制剂
|
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
|
GB9824893D0
(en)
*
|
1998-11-12 |
1999-01-06 |
Smithkline Beckman Corp |
Novel method of treatment
|
|
US20040081697A1
(en)
*
|
1998-11-12 |
2004-04-29 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
|
ID30237A
(id)
*
|
1998-12-24 |
2001-11-15 |
Metabasis Therapeutics Inc |
KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
|
|
US7001746B1
(en)
*
|
1999-01-29 |
2006-02-21 |
Artecel Sciences, Inc. |
Methods and compositions for the differentiation of human preadipocytes into adipocytes
|
|
WO2000055318A2
(en)
*
|
1999-03-15 |
2000-09-21 |
University Of British Columbia |
Abc1 polypeptide and methods and reagents for modulating cholesterol levels
|
|
US7407978B2
(en)
*
|
1999-04-06 |
2008-08-05 |
Theracos, Inc. |
Heterocyclic analogs of diphenylethylene compounds
|
|
US7563775B2
(en)
*
|
2000-11-01 |
2009-07-21 |
Betty C. Villafuerte |
Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
|
|
US20060154864A1
(en)
*
|
1999-11-01 |
2006-07-13 |
Emory University |
Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
|
|
FR2802814B1
(fr)
*
|
1999-12-23 |
2002-02-22 |
Aventis Pharma Sa |
Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
|
|
ES2218338T3
(es)
*
|
2000-04-13 |
2004-11-16 |
Pfizer Products Inc. |
Efecto sinergico de gliburida y milrinona.
|
|
GB0014969D0
(en)
*
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
|
KR200249057Y1
(ko)
*
|
2001-03-22 |
2001-10-19 |
김진환 |
뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
|
|
US6492339B1
(en)
|
2001-05-23 |
2002-12-10 |
Insmed, Incorporated |
Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
|
|
SE0101982D0
(sv)
*
|
2001-06-01 |
2001-06-01 |
Astrazeneca Ab |
Pharmaceutical combination
|
|
US7785627B2
(en)
*
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
AU2003272504A1
(en)
|
2002-09-20 |
2004-04-08 |
Andrx Labs Llc |
Multistage formulation containing a biguanide and thiazolidindione derivatives
|
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
US20040147564A1
(en)
*
|
2003-01-29 |
2004-07-29 |
Rao Vinay U. |
Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
|
|
CN1874774B
(zh)
|
2003-10-31 |
2011-04-13 |
武田药品工业株式会社 |
包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
|
|
MXPA04009236A
(es)
*
|
2004-09-23 |
2006-03-27 |
Jorge Luis Rosado Loria |
Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
|
|
WO2006074278A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Mitsunori Ono |
Compositions for treating diabetes or obesity
|
|
TW200722088A
(en)
*
|
2005-05-27 |
2007-06-16 |
Sankyo Co |
Diabetes remedy
|
|
US20090286722A1
(en)
*
|
2005-09-08 |
2009-11-19 |
Utech Limited |
Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
|
|
EP1943274A2
(en)
*
|
2005-09-08 |
2008-07-16 |
Uutech Limited |
Treatment of diabetes related obesity
|
|
WO2007059372A2
(en)
*
|
2005-11-09 |
2007-05-24 |
St. Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
|
MXPA05013220A
(es)
*
|
2005-12-06 |
2007-06-05 |
Leopoldo De Jesus Espinosa Abdala |
Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
|
|
ZA200805147B
(en)
|
2005-12-22 |
2010-05-26 |
Takeda Pharmaceutical |
Solid preparation
|
|
WO2008026668A1
(en)
*
|
2006-08-31 |
2008-03-06 |
Daiichi Sankyo Company, Limited |
Medicinal composition containing insulin resistance improving agent
|
|
PL2068909T3
(pl)
|
2007-03-30 |
2012-09-28 |
Ambrx Inc |
Modyfikowane polipeptydy fgf-21 i ich zastosowanie
|
|
CN101932308B
(zh)
|
2007-12-04 |
2014-11-05 |
治疗医药股份有限公司 |
改良的配制剂和用于冻干的方法及由此提供的冻干物
|
|
FR2928836B1
(fr)
*
|
2008-03-21 |
2011-08-26 |
Servier Lab |
Forme galenique secable permettant une liberation modifiee du principe actif
|
|
RU2630577C2
(ru)
*
|
2008-12-04 |
2017-09-11 |
Чунси ЮЙ |
Композиции интенсивного проникновения и их применение
|
|
US20110065756A1
(en)
*
|
2009-09-17 |
2011-03-17 |
De Taeye Bart M |
Methods and compositions for treatment of obesity-related diseases
|
|
BR112012011237A2
(pt)
|
2009-11-13 |
2019-09-24 |
Univ Tokyo |
agente terapêutico e profilático para diabetes
|
|
CA2806619C
(en)
|
2010-05-24 |
2018-05-22 |
Ozstar Therapeutics Pty Ltd |
Anti-diabetic compositions and methods
|
|
EP4039208B1
(en)
|
2011-01-19 |
2023-08-30 |
Fractyl Health, Inc. |
Devices for the treatment of tissue
|
|
BR112014012401A2
(pt)
|
2011-11-23 |
2017-06-13 |
Ozstar Therapeutics Pty Ltd |
composição sinérgica melhorada; método de tratamento profilático ou terapêutico de diabetes; método de melhorar a eficácia do tratamento da diabetes por sulfonilureia em um indivíduo recebendo uma terapia anti-diabética de sulfonilureia; método de tratar hiperglicemia; e método de impedir o desenvolvimento ou melhorar os efeitos colaterais ou as condições em um indivíduo tratado com uma sulfonilureia e/ou uma sulfonamida e/ou derivados e/ou metabólitos dos mesmos
|
|
CN103159651B
(zh)
*
|
2011-12-14 |
2015-06-17 |
安徽贝克联合制药有限公司 |
磺酰脲胍及其制备方法和用途
|
|
AU2013226062B2
(en)
|
2012-02-27 |
2017-10-19 |
Fractyl Health, Inc. |
Heat ablation systems, devices and methods for the treatment of tissue
|
|
KR102231179B1
(ko)
|
2012-04-19 |
2021-03-22 |
프랙틸 래브러토리스 인코포레이티드 |
조직 팽창 디바이스들, 시스템들, 및 방법들
|
|
EP3714826A1
(en)
|
2012-07-30 |
2020-09-30 |
Fractyl Laboratories, Inc. |
Electrical energy ablation systems and devices for the treatment of tissue
|
|
WO2014026055A1
(en)
|
2012-08-09 |
2014-02-13 |
Fractyl Laboratories Inc. |
Ablation systems, devices and methods for the treatment of tissue
|
|
EP2903626A4
(en)
|
2012-10-05 |
2016-10-19 |
Fractyl Lab Inc |
METHODS, SYSTEMS AND DEVICES FOR CARRYING OUT MULTIPLE TREATMENTS OF A PATIENT
|
|
EP3003461B1
(en)
|
2013-06-04 |
2019-05-01 |
Fractyl Laboratories, Inc. |
Systems and devices for reducing the luminal surface area of the gastrointestinal tract
|
|
WO2015038973A1
(en)
|
2013-09-12 |
2015-03-19 |
Fractyl Laboratories, Inc. |
Systems, methods and devices for treatment of target tissue
|
|
AU2014352874B2
(en)
|
2013-11-22 |
2019-03-14 |
Fractyl Health, Inc. |
Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
|
|
US10959774B2
(en)
|
2014-03-24 |
2021-03-30 |
Fractyl Laboratories, Inc. |
Injectate delivery devices, systems and methods
|
|
US11185367B2
(en)
|
2014-07-16 |
2021-11-30 |
Fractyl Health, Inc. |
Methods and systems for treating diabetes and related diseases and disorders
|
|
US9844641B2
(en)
|
2014-07-16 |
2017-12-19 |
Fractyl Laboratories, Inc. |
Systems, devices and methods for performing medical procedures in the intestine
|
|
WO2016011269A1
(en)
*
|
2014-07-16 |
2016-01-21 |
Fractyl Laboratories, Inc. |
Methods and systems for treating diabetes and related diseases and disorders
|
|
CN107108710B
(zh)
|
2014-10-24 |
2022-02-15 |
百时美施贵宝公司 |
修饰的fgf-21多肽及其用途
|
|
US12274703B2
(en)
|
2017-12-21 |
2025-04-15 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising a dementia
|
|
US12310967B2
(en)
|
2017-12-21 |
2025-05-27 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
|
|
CN108079000A
(zh)
*
|
2018-02-01 |
2018-05-29 |
湖南博隽生物医药有限公司 |
一种治疗糖尿病的药物组合物及其制备方法
|
|
WO2020132378A2
(en)
|
2018-12-22 |
2020-06-25 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising depression
|
|
US12350264B2
(en)
|
2019-11-22 |
2025-07-08 |
Brown University |
Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
|
|
US12403138B2
(en)
*
|
2019-11-22 |
2025-09-02 |
Brown University |
Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
|
|
WO2021146535A1
(en)
|
2020-01-15 |
2021-07-22 |
Fractyl Laboratories, Inc. |
Automated tissue treatment devices, systems, and methods
|